• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Transplant International

    Transplant International

    JournalISSN 0934-0874eISSN 1432-2277中科院 医学 3区

    年发文量

    研究主题

    论文(264844)

    排序
    1NewFive-year Outcomes of Machine Perfusion Versus Static Cold Storage in Controlled Donation after Circulatory Death Kidney Transplantation: a Binational Cohort Study
    Alexandros K. Papageorgiou,Fabian Kalt,Fabian Rössler,Marcel Schneider,Jan Philipp Jonas,Kerstin Hübel,Harmacek Dusan,Benoît Mesnard, Mara Cvijetic,Julien Branchereau, Sarvar Abdurakhmonov, Saydimurad Ismailov,

    While hypothermic machine perfusion reduces delayed graft function (DGF) after kidney transplantation, its long-term benefits in controlled donation after circulatory death (DCD) are uncertain in real-world practice. We evaluated whether perfusion improves 5-year death-censored graft survival compared to static cold storage in DCD by benchmarking outcomes against those of donation after brain death (DBD). After analyzing the United Network for Organ Sharing and Swiss Transplant Cohort Study registries, we created a 1:1 propensity-score-matched cohort to balance baseline characteristics. Among 44,552 DCD recipients (34,739 with perfusion; 9,813 with cold storage) and 180,898 DBD controls, the matched 5-year death-censored graft survival rate was 84.8% with perfusion versus 87.4% with cold storage (hazard ratio 1.08; P = 0.19). Perfusion significantly reduced the rate of DGF (35.7% vs. 44.9%; P < 0.001), while the rates of primary nonfunction and acute rejection were comparable. Both DCD groups achieved long-term outcomes equivalent to those of the DBD cohort. In conclusion, while machine perfusion confers a substantial early reduction in delayed graft function, static cold storage continues to deliver excellent 5-year graft survival. Both strategies yield excellent long-term outcomes comparable to those of DBD transplants. Crucially, these findings support expanding DCD programs to include older donors as a vital strategy to increase transplantation rates and reduce waitlist mortality. To optimize outcomes in these older DCD grafts, clinicians should aim to limit donor comorbidity, keep total ischemia time below 12–15 h, and utilize continuous rather than end-ischemic machine perfusion whenever logistically feasible.

    2026
    引用
    AI阅读
    加入学术空间
    2NewIncidence of Cause-Specific Mortality after Kidney Transplantation: a Multicenter French Cohort Study
    Thomas Beaudrey, François Séverac, Sébastien Loewert,Christophe Masset,Fanny Buron,Philippe Gatault,Marie-Pascale Morin,Coralie Poulain,Antoine Thierry,Dominique Bertrand,Valérie Chatelet,Yannick Le Meur,

    The incidence and temporal distribution of causes of death after kidney transplantation are insufficiently described in the literature, particularly in the first months after graft failure. We aimed to describe cause-specific mortality across the kidney transplant course in a French multicenter cohort. We included adult recipients of a kidney transplantation performed in 14 university hospitals between 2008 and 2014. We analyzed causes of death with graft function or occurring until 6 months after graft failure, classified as infection-related, cancer-related, cardiovascular disease-related, other causes, or unknown causes. Cause-specific hazard models were used to assess baseline factors associated with each cause. Among 6,935 recipients, 1,324 died during follow-up. The 10-year cumulative incidences of infection-related, cancer-related and cardiovascular disease-related death were respectively 5.5%, 5.0% and 4.5%. Cardiovascular deaths predominated in the earliest post-transplant period, infections during early follow-up, and cancers became increasingly prominent later. The early post-graft failure period was characterized by high mortality and predominance of infection-related deaths. Baseline factors associated with mortality varied across causes of death. Causes of death after transplantation are dominated by three leading affections (infections, cancers and cardiovascular diseases), together accounting for nearly two-thirds of all deaths, with only modest differences in long-term incidence between them.

    2026
    引用
    AI阅读
    加入学术空间
    3NewRestoring Liver Transplant Candidacy with Transcatheter Aortic Valve Implantation in a Patient with Cirrhosis and Severe Aortic Stenosis
    Ignacio Hernandez-Gonzalez,Gloria Sánchez-Antolín, Sara Rioja Abad,Natalia Marcos Carrasco,Enrique Asensio Díaz, Juan Carlos Muñoz San José

    The convergence of severe aortic stenosis and end-stage liver disease in orthotopic liver transplantation (OLT) candidates is an increasingly recognized clinical challenge, driven by the shared cardiometabolic risk factor profile underpinning both metabolic dysfunctionassociated steatotic liver disease (MASLD) and degenerative valvular disease. Severe aortic stenosis constitutes a contraindication to OLT due to the hemodynamic burden it imposes perioperatively, while advanced cirrhosis frequently precludes conventional surgical aortic valve replacement (SAVR). In patients with advanced cirrhosis, cardiac surgery may carry a prohibitive risk owing to coagulopathy, immune dysfunction, poor nutritional status, renal impairment, and the severity of liver disease and its complications. The 2024 EASL Clinical Practice Guidelines on liver transplantation and the 2025 International Liver Transplantation Society and the Liver Intensive Care Group of Europe guidelines for cardiovascular assessment before liver transplantation explicitly mandate structured preoperative risk stratification, including the treatment of significant structural heart disease, as part of the pre-transplant workup [1,2]. Transcatheter aortic valve implantation (TAVI) has emerged as the solution to this therapeutic impasse. We report a case in which TAVI was used as a bridge to successfully restore OLT eligibility.A 63-year-old male with hypertension, dyslipidemia, type 2 diabetes mellitus, former smoking (30 pack-years), and chronic alcohol misuse presented in March 2023 with acute pulmonary oedema (APE) and type 2 myocardial infarction due to acute anemia from large esophageal varices, managed by endoscopic band ligation. He also had a history of STelevation myocardial infarction in 2013, treated with percutaneous revascularization of the circumflex artery, and, in accordance with both current and contemporary recommendations, was receiving indefinite aspirin therapy [3]. The workup confirmed mixed-etiology (alcoholic and MASLD-related) cirrhosis with portal hypertension, right portal vein thrombosis, and hepatocellular carcinoma (HCC) within up-to-seven criteria. Coronary angiography confirmed patency of the previously stented artery. Transthoracic echocardiography demonstrated severe aortic stenosis (peak gradient 66 mmHg, mean gradient 43 mmHg, valve area 0,52 cm2/m2) with left ventricular systolic function at the lower limit of normal (left ventricular ejection fraction [LVEF] by the biplane Simpson's method 55%). Two episodes of grade II hepatic encephalopathy occurred during the same admission. The patient was deemed ineligible for surgical aortic valve replacement owing to prohibitive perioperative morbidity and mortality in the setting of decompensated cirrhosis .In October 2024, TAVI was performed under local anesthesia with conscious sedation. The procedure was uneventful and hemodynamically well tolerated, with no clinically significant bleeding related to coagulopathy or portal hypertension and no new conduction disturbances. After full recovery, the patient was referred to complete the pretransplant work-up, including repeat computed tomography, which confirmed that the HCC remained within the up-to-seven criteria. Once preserved left ventricular systolic function (LVEF 60%) and normal function of the bioprosthetic aortic valve (mean gradient 9 mmHg) were confirmed, the case was reviewed by the liver transplant committee, and the patient was listed for OLT in April 2025.In August 2025, OLT was performed uneventfully from a cardiac perspective. Intraoperative monitoring included electrocardiography, invasive arterial pressure, and central venous pressure. Aspirin 100 mg was maintained throughout the perioperative period. Postoperative complications included hepatic artery thrombosis requiring reexploration, thrombectomy, and splenic artery ligation; and caecal perforation with polymicrobial peritonitis (Streptococcus sanguinis and Bacteroides thetaiotaomicron), treated surgically. No cardiac complications were documented, and echocardiography at discharge confirmed preserved LVEF and a normally functioning bioprosthetic valve. At fourteen months of follow-up, the patient remains asymptomatic in NYHA class I, with no readmissions, and serial echocardiograms confirm durable prosthesis function (Figure 1). This case illustrates an increasingly prevalent scenario: an OLT candidate with significant structural heart disease in the setting of shared cardiometabolic risk factors. TAVI is a viable treatment option for severe aortic stenosis in patients across different stages of liver disease, with careful and individualized patient selection [4]. Compared with surgical aortic valve replacement (SAVR), TAVI appears to be associated with a shorter length of hospital stay, lower healthcare costs, fewer complications, and lower short-term mortality [5]. However, long-term data on TAVI outcomes in patients with cirrhosis are limited. As a bridge to OLT specifically, Levy et al. reported three patients with cirrhosis who regained transplant eligibility after TAVI [6], and Caughron et al. found that 7 of 29 patients with end-stage liver or renal disease undergoing TAVI were subsequently listed for transplantation [7]. In addition, the safety of major abdominal surgery after TAVI has been documented across all post-procedural time intervals [10]. Careful patient selection, guided by the severity of liver disease and renal impairment, is critical to avoid futile interventions [8]. Regarding the continuation of antithrombotic therapy, American and European guidelines recommend maintaining low-dose aspirin in patients with prior percutaneous coronary intervention undergoing non-cardiac surgery [9,10]. This strategy appeared to be acceptable in our experience. These observations suggest that TAVI may be considered a means of restoring OLT candidacy in highly selected patients with cirrhosis, provided that a coordinated multidisciplinary approach is applied. Given the limited evidence, further studies are needed to confirm these findings and define the appropriate candidates.

    2026
    引用
    AI阅读
    加入学术空间
    4NewPIRCHE-II Epitope Burden Associates with Innate Immune Phenotypes after Liver Transplantation
    Aránzazu Caballero-Marcos, Laura Díaz-Muñoz,Marta Puerto,Raquel Alenda, Christian Ruiz-Martín,Ainhoa Fernández-Yunquera,Fernando Díaz-Fontenla,Mario Romero,María Fernández-Martínez, Álvaro Morales, Patricia Duque-González,Antonio Balas,

    Whether donor–recipient HLA epitope mismatch burden is associated with specific peripheral immune phenotypes in clinically stable liver transplant (LT) recipients remains unclear. In this exploratory translational study, we evaluated whether HLA epitope mismatch burden, quantified by the PIRCHE-II score, is associated with coordinated peripheral immune configurations in 14 clinically stable LT recipients. Prespecified biologically informed immune cell ratios spanning innate and adaptive compartments were analyzed within a constrained hierarchical framework using Benjamini–Hochberg false discovery rate correction across four primary endpoints; secondary exploratory analyses evaluated broader immune families using within-family correction. Higher PIRCHE-II scores were associated predominantly with innate immune phenotypes, particularly increased proportions of nonclassical monocytes and CD56+CD16high natural killer cells, representing the most robust associations across analytical frameworks, with directionally consistent but statistically attenuated associations observed in CD8+CD38+ T cells and IgM+IgD+ B-cell compartments in exploratory analyses. These associations occurred without evidence of overt systemic inflammation or major changes in absolute immune cell counts, indicating a qualitative, innate-predominant immune skewing rather than generalized immune activation. These findings support specific and consistent peripheral immune phenotypes associated with epitope mismatch burden in clinically stable LT recipients, although interpretation remains limited by the small sample size and exploratory design.

    2026
    引用
    AI阅读
    加入学术空间
    5NewExtracorporeal Life Support in Adult Lung Transplantation: a Survey of Italian Lung Transplant
    Andrea Costamagna,Domenico Pinelli, Anna Laureys,Stefania Camagni, Samuele Nicotra,Filippo Antonacci, Lorenzo P. A. Rosso,Ilaria Righi,Alessandro Bertani, Maria Scarlata,Marco Schiavon,Giorgio Cannone,

    The use of extracorporeal life support (ECLS) during lung transplantation has evolved substantially. Despite recent international consensus recommendations, significant variability persists. We conducted a national survey to describe contemporary practice patterns among Italian lung transplant centres. A 39-item, web-based survey was developed and distributed to all nine Italian lung transplant centres. The survey addressed indications for ECLS, technical aspects of extracorporeal support, anticoagulation and postoperative management. The response rate was 100%. Seven centres (77.8%) reported selective use of ECLS, whereas two (22.2%) routinely used ECLS during bilateral lung transplantations. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) was the preferred intraoperative support modality in seven centres (77.8%), while two centres (22.2%) preferred cardiopulmonary bypass. Considerable variability was observed in patient selection, anticoagulation, cannulation strategies, postoperative ECLS continuation and weaning practices. Substantial variability remains in ECLS management among Italian lung transplant centres, despite recent international consensus recommendations. These findings provide a contemporary national overview of ECLS practice and highlight the need for further patient-level and outcome-based evaluation of intraoperative ECLS strategies.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 264844 篇论文

    高被引作者

    作者引用发文
    Jordi Bruix75859304
    Arun J. Sanyal66827888
    Zobair Younossi61693699
    Josep M. Llovet59478247
    Jaime Bosch47576557
    Guadalupe Garcia-Tsao41598272
    Vicente Arroyo41344449
    Elizabeth M. Brunt39686140
    Patrick S. Kamath34610359
    Pere Ginès33898421

    高产作者

    作者引用发文
    Dorry L. Segev244751165
    Stefan Zeuzem29287903
    Arun J. Sanyal66827888
    Shiv Kumar Sarin13467866
    H.L.A. (Harry) Janssen20341779
    Heiner Wedemeyer15396766
    Michael Trauner18014755
    Thomas Berg17712720
    Zobair Younossi61693699
    Arthur Matas23633647

    相关期刊

    Clinical Transplantation
    Transplantation Reviews
    Transplantation Proceedings
    Transplantation
    Annals of transplantation
    Current opinion in organ transplantation
    World journal of transplantation
    Current Transplantation Reports
    Transplantation direct
    American Journal of Transplantation